Close Menu

The $1,000 genome won't do any good for science if researchers can't interpret it, says Adina Mangubat, CEO of Spiral Genetics, in Xconomy. While industry has focused most of its time and energy to creating better ways to sequence a genome, it has "largely ignored the computational power required to extract and analyze the genomic data in a timeframe that keeps it relevant," Mangubat adds. And most labs aren't prepared for all that data.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.